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The ever increasing emphasis on complex reporting guidelines is getting in the way of designing 
and conducting good clinical trials, say Jeremy Howick, Rebecca Webster, and J André 
Knottnerus. But David Moher argues that, while following the guidelines can be frustrating, 
such complexity remains necessary and is improving research, not impeding it 
Yes—Jeremy Howick, Rebecca Webster, and J André Knottnerus 
In 1996 a group of medical journal editors, clinical trialists, epidemiologists, and 
methodologists met in Chicago to develop a checklist to help researchers report the results of 
their clinical trials completely and transparently.1 The result was the Consolidated Standards of 
Reporting Trials (Consort), which has aimed to improve reporting of randomised controlled trials 
(RCTs) ever since. 
The original 1996 statement included a half page guide embedded in a three page explanatory 
document.2 The updated 2010 Consort statement includes 25 items embedded in a 28 page paper, 
as well as a separate explanatory document. That’s just the basic version. There are versions of 
Consort for trials of herbal treatments, orthodontic treatments, feasibility, and at least 25 other 
subtypes.3 And that’s just Consort; many other reporting guidelines have been developed since 
1996. 
Multiple guidelines are often required for a single study, each with a host of supplementary 
documents. Identifying, understanding, and implementing these guidelines takes time and effort. 
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This would be justified if these efforts all improved study quality—or better still, patient 
outcomes. Such evidence is absent. 
The fact is that guideline developers measure their success by checking to see how well 
researchers adhere to the guidance.4 Such efforts often reveal that the guidelines are barely used.5 
Worse, checking whether guidelines are used doesn’t tell us whether the guidelines (in their 
current form) are useful for improving research in the first place. 
Perverse incentives 
In addition, since successful (or successfully followed) guidelines lead to multiple 
publications and are widely cited, perverse incentives are likely to proliferate the problem of too 
many guidelines. Further, the proliferation of complex reporting guidelines can remove the focus 
away from designing and conducting good trials or from detecting poor trial design. This is 
supported by the following reasons. 
First, generating, identifying, studying, and referencing the complex web of guidelines is a 
time consuming process that diverts scarce resources from designing clinically sound hypotheses 
and conducting good research. Second, compliance with reporting guidelines creates a veneer of 
detailed sound reporting that can distract from fundamental problems in a trial. 
Trials of questionable value have continued to thrive despite Consort. In 2015, for example, 
researchers conducted a placebo controlled trial looking at the efficacy of a three month 
formulation of paliperidone palmitate in patients with schizophrenia,6 finding that the treatment 
was superior to placebo. The trial was well reported in terms of adherence to the reporting 
guidance. However, previously published systematic reviews7 had already established the 
efficacy of antipsychotics for reducing relapse in patients with schizophrenia. The authors did 
not explain why a placebo controlled trial of a new intervention was conducted instead of a trial 
of a new intervention versus a proven therapy.8 
Another well-reported trial suggested that the diabetes drug rosiglitazone effectively lowered 
blood glucose (a surrogate outcome). It was subsequently found that the drug increased 
cardiovascular events (the outcome relevant to patients).9 
In another example, three of four well reported industry sponsored trials evaluating newer 
antihypertensive drugs used atenolol as the comparator, although a low dose thiazide diuretic had 
been found to be superior.10 
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These examples show how a well reported trial with inappropriate comparators or outcomes 
is wasteful and may lead to the adoption of useless or even harmful interventions that lack 
benefits. They also show that the complex web of reporting guidelines the researchers 
meticulously followed failed to catch this, improve the trial design, or prevent such trials from 
happening in the first place. 
The simpler the better 
Counterintuitively, simpler guidelines may be more rigorous.11 For example, Green and Mehr 
introduced a simple clinical guideline to determine whether a patient with chest pain should be 
sent to a coronary care unit.12 This resulted in better sensitivity and specificity than a complex, 
50 question instrument. 
Moher argues that “. . . such as with pharmaceuticals, we should be more cautious about 
recommending the use of reporting guidelines without evidence of effectiveness.”13 We agree. In 
our view, the effectiveness of the current state of affairs—namely, many complex guidelines—
must be formally compared with the use of vastly simplified, single guidelines. 
The proliferation of increasingly complex guidelines needs to be tamed in the same way as 
the problem of too much medicine: with evidence based evaluation. 
No—David Moher 
Researchers have always struggled to report their randomised trials (RCTs)[OK?] completely 
and transparently.14 This is why experts involved in the process, from journal editors to clinicians 
and methodologists, met as early as 1993 to find a solution. The resulting guidelines15 16 include 
the 1994 publication of [or “a 1994 publication by”?] the Standards of Reporting Trials (Sort) 
group[OK?], aiming to provide prospective authors with guidance on reporting their trial design, 
methods, and results. They were not alone: Drummond Rennie, a deputy editor of JAMA,[OK?] 
was a member of a separate initiative called Asilomar that met about six months later with a 
similar remit to Sort’s. He brought both groups together, resulting in the original Consort 
statement in 1996. 
Consort had two fundamental goals at its inception. Its longer term goal is to improve the 
quality of RCTs through better reporting, which admittedly remains distant.17 But its immediate 
goal of improving the transparency and completeness of reporting RCTs is arguably being 
achieved, even if the implementation is complex. 
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For example, reporting of allocation concealment in reports of RCTs is more complete in 
journals that endorse the Consort guidance than in journals that do not.5 The development of the 
Spirit standard for trial protocols in 2013 has brought further improvement in the transparency of 
protocols for RCTs.18 If authors have adequately described the method used for allocation 
concealment in their protocol, and if there has been no deviation of this during the trial, it should 
be easy to include this information in the final report of the completed trial. 
Clear problems, not so clear solutions 
Undoubtedly, since Consort’s birth the number of guidelines has proliferated: there are 
numerous extensions to Consort, while Equator (the Enhancing the QUAlity and Transparency 
Of health Research Network) contains a comprehensive open access library of more than 400 
reporting guidelines. 
Admittedly, this can be confusing for the people conducting the trials, particularly if they are 
required to use multiple guidance. Journals also differ in their endorsement, often not 
recommending that peer reviewers use reporting guidelines when peer reviewing a manuscript, 
and most [journals?] have not publicly indicated whether they monitor their endorsement of 
reporting guidelines. Some reporting guidelines have never been cited,19 suggesting a lack of use. 
But while the problems are clear, I think that the solutions are more complex. Even if 
guidance were made simpler, the evidence underpinning reporting recommendations takes time 
to accumulate. When Consort was created in 1996, there was little evidence about the 
consequences of outcome reporting biases or spin on the results and interpretation of RCTs. We 
know better today, and reporting guidelines need to be updated to reflect this knowledge. 
While providing evidence will always be the main justification for reporting items in clinical 
trials, clarity and common sense are other important reasons. Authors who report their trial 
design, methods, and results completely and transparently may have an easier time disseminating 
their message. And, without an audit of the publication of RCT results, it’s very difficult to 
continue to improve or change their practice for the better. Feedback to authors would help, but I 
am unaware of any journal or publisher that provides this type of audit and feedback on its 
website or to individual researchers.[OK?] 
Incentives 
Just making guidelines simpler would not necessarily increase the number of people using 
them or improve the quality of reporting. A bigger problem is that authors are not incentivised or 
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rewarded for using reporting guidelines in the first place. What if researchers were assessed as to 
whether they used a guideline when reporting their research, rather than the ubiquitous “publish 
or perish”?20 The metadata are available to enable automated compilation of this information. 
Researchers could include this information in their curriculum vitae. 
It’s not that the problems of complexity are not acknowledged or that no efforts are under 
way to fix them. Journal editors have repeatedly urged the use of technology to help authors 
adhere to reporting guidelines. Authors can use Penelope (an Equator wizard)[OK?], and 
members of the newly merged Spirit and Consort executive are working to incorporate some of 
the key extensions into a single checklist. 
While I understand why busy clinicians call for simpler guidance, I question the belief that 
this would improve the quality of clinical trial reporting. Conducting trials, even pragmatic real 
world trials, is complex and takes time. Shouldn’t we have a similar philosophy for reporting 
them? 
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